FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset

The Food and Drug Administration (FDA) granted regular approval for Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).